Cargando…

Tumor Microenvironment—A Short Review of Cellular and Interaction Diversity

SIMPLE SUMMARY: Scientists around the world have long been interested in understanding the biology of cancer. Numerous studies that have been carried out so far clearly show that the development of cancer stems not only from a genetic mutation, but also from a network of interconnections between che...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bożyk, Aleksandra, Wojas-Krawczyk, Kamila, Krawczyk, Paweł, Milanowski, Janusz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9220289/ https://www.ncbi.nlm.nih.gov/pubmed/35741450 http://dx.doi.org/10.3390/biology11060929

Ejemplares similares

Clinical Application Perspectives of Lung Cancers 3D Tumor Microenvironment Models for In Vitro Cultures
por: Wieleba, Irena, et al.
Publicado: (2022)

Correlation between KRAS, NRAS and BRAF mutations and tumor localizations in patients with primary and metastatic colorectal cancer
por: Bożyk, Aleksandra, et al.
Publicado: (2021)

The influence of different culture microenvironments on the generation of dendritic cells from non-small-cell lung cancer patients
por: Krawczyk, Paweł, et al.
Publicado: (2007)

Future Prospects of Immunotherapy in Non-Small-Cell Lung Cancer Patients: Is There Hope in Other Immune Checkpoints Targeting Molecules?
por: Krzyżanowska, Natalia, et al.
Publicado: (2022)

Immunotherapy in Non-Small-Cell Lung Cancer Patients with Driver Alterations: A New Strategy?
por: Krzyżanowska, Natalia, et al.
Publicado: (2022)

Beyond PD-L1 Markers for Lung Cancer Immunotherapy
por: Wojas-Krawczyk, Kamila, et al.
Publicado: (2019)

Mechanisms of resistance to reversible inhibitors of EGFR tyrosine kinase in non-small cell lung cancer
por: Krawczyk, Paweł, et al.
Publicado: (2012)

Immunoprofiling: An Encouraging Method for Predictive Factors Examination in Lung Cancer Patients Treated with Immunotherapy
por: Wojas-Krawczyk, Kamila, et al.
Publicado: (2021)

In vitro preliminary study on different anti-PD-1 antibody concentrations on T cells activation
por: Wieleba, Irena, et al.
Publicado: (2022)

HER2 gene assessment in liquid biopsy of gastric and esophagogastric junction cancer patients qualified for surgery
por: Grenda, Anna, et al.
Publicado: (2020)

Evaluation of ALK gene rearrangement in central nervous system metastases of non-small-cell lung cancer using two-step RT-PCR technique
por: Nicoś, M., et al.
Publicado: (2017)

Effect of TOP2A and ERCC1 gene polymorphisms on the efficacy and toxicity of cisplatin and etoposide-based chemotherapy in small cell lung cancer patients
por: Nicoś, Marcin, et al.
Publicado: (2020)

Aptamers in Non-Small Cell Lung Cancer Treatment
por: Wieleba, Irena, et al.
Publicado: (2020)

Double Guard Efficiency and Safety—Overcoming Resistance to Immunotherapy by Blocking or Stimulating Several Immune Checkpoints in Non-Small Cell Lung Cancer Patients
por: Kalinka, Ewa, et al.
Publicado: (2023)

The Application of Real-Time PCR Technique to Detect Rare Cell Clones with Primary T790M Substitution of EGFR Gene in Metastases of Non-small Cell Lung Cancer to Central Nervous System in Chemotherapy Naive Patients
por: Powrózek, Tomasz, et al.
Publicado: (2014)

EGFR activating mutations detected by different PCR techniques in Caucasian NSCLC patients with CNS metastases: short report
por: Kamila, Wojas-Krawczyk, et al.
Publicado: (2013)

Polymorphisms of Genes Encoding Multidrug Resistance Proteins as a Predictive Factor for Second-Line Docetaxel Therapy in Advanced Non-small Cell Lung Cancer
por: Szczyrek, Michał, et al.
Publicado: (2016)

Failure of Immunotherapy—The Molecular and Immunological Origin of Immunotherapy Resistance in Lung Cancer
por: Błach, Justyna, et al.
Publicado: (2021)

Two Complementarity Immunotherapeutics in Non-Small-Cell Lung Cancer Patients—Mechanism of Action and Future Concepts
por: Wojas-Krawczyk, Kamila, et al.
Publicado: (2021)

MET Gene Dysregulation as a Promising Therapeutic Target in Lung Cancer—A Review
por: Terlecka, Paulina, et al.
Publicado: (2021)

Polymorphism of Baculoviral Inhibitor of Apoptosis Repeat-Containing 5 (BIRC5) Can Be Associated with Clinical Outcome of Non-Small Cell Lung Cancer
por: Szczyrek, Michał, et al.
Publicado: (2022)

Interactions between Dietary Micronutrients, Composition of the Microbiome and Efficacy of Immunotherapy in Cancer Patients
por: Frąk, Małgorzata, et al.
Publicado: (2022)

Immunohistochemical assays incorporating SP142 and 22C3 monoclonal antibodies for detection of PD-L1 expression in NSCLC patients with known status of EGFR and ALK genes
por: Krawczyk, Paweł, et al.
Publicado: (2017)

The Incidence of EGFR-Activating Mutations in Bone Metastases of Lung Adenocarcinoma
por: Krawczyk, Paweł, et al.
Publicado: (2013)

Crizotinib efficacy in advanced non-squamous NSCLC patients with ALK or ROS1 rearrangement
por: Krawczyk, Paweł, et al.
Publicado: (2021)

The analysis of ALK gene rearrangement by fluorescence in situ hybridization in non-small cell lung cancer patients
por: Wojas-Krawczyk, Kamila, et al.
Publicado: (2013)

New Genetic Technologies in Diagnosis and Treatment of Cancer of Unknown Primary
por: Krawczyk, Paweł, et al.
Publicado: (2022)

Molecular and Clinical Premises for the Combination Therapy Consisting of Radiochemotherapy and Immunotherapy in Non-Small Cell Lung Cancer Patients
por: Frąk, Małgorzata, et al.
Publicado: (2021)

Diet, Microbiome, and Cancer Immunotherapy—A Comprehensive Review
por: Szczyrek, Michał, et al.
Publicado: (2021)

Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients
por: Krawczyk, Paweł, et al.
Publicado: (2014)

Imperfect Predictors for Lung Cancer Immunotherapy—A Field for Further Research
por: Wojas-Krawczyk, Kamila, et al.
Publicado: (2020)

Septin 9 promoter region methylation in free circulating DNA—potential role in noninvasive diagnosis of lung cancer: preliminary report
por: Powrózek, Tomasz, et al.
Publicado: (2014)

Letter to the editor concerning first-line therapy with afatinib – an irreversible EGFR TKI and overall survival of NSCLC patients with EGFR gene mutations
por: Krawczyk, Paweł, et al.
Publicado: (2015)

The Role of Intratumor Heterogeneity in the Response of Metastatic Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitors
por: Nicoś, Marcin, et al.
Publicado: (2020)

Non-Small-Cell Lung Cancer Patients with Coexistence of High PD-L1 Expression and RET Fusion—Which Path Should We Follow? Case Reports and Literature Review
por: Knetki-Wróblewska, Magdalena, et al.
Publicado: (2022)

Breaking the ‘Undruggable’ Barrier: Anti-PD-1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer Patients with KRAS Mutations—A Comprehensive Review and Description of Single Site Experience
por: Chmielewska, Izabela, et al.
Publicado: (2023)

Assessment of EGFR gene mutations in circulating free DNA in monitoring of response to EGFR tyrosine kinase inhibitors in patients with lung adenocarcinoma
por: Nicoś, Marcin, et al.
Publicado: (2019)

Endocrine Adverse Events of Nivolumab in Non-Small Cell Lung Cancer Patients—Literature Review
por: Dudzińska, Marta, et al.
Publicado: (2020)

Efficacy of Osimertinib in Lung Squamous Cell Carcinoma Patients with EGFR Gene Mutation–Case Report and a Literature Review
por: Rekowska, Anna, et al.
Publicado: (2022)

Viral Infection and Lung Cancer Immunotherapy
por: Kalinka, Ewa, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2t300hdtihn2kn917ipngrufj1